Dermatological Changes during Menopause and HRT: What to Expect?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gong, D.; Sun, J. Early age at natural menopause and risk of cardiovascular and all-cause mortality: A meta-analysis of prospective observational studies. Int. J. Cardiol. 2016, 203, 115–119. [Google Scholar] [CrossRef] [PubMed]
- Mirmirani, P. Hormonal changes in menopause: Do they contribute to women’s “midlife hair crisis”? Br. J. Dermatol. 2011, 165, 7–11. [Google Scholar] [CrossRef] [PubMed]
- Verdier-Sevrain, S.; Bonte, F. Biology of estrogens in skin: Implications for skin aging. Exp. Dermatol. 2006, 15, 83–94. [Google Scholar] [CrossRef] [PubMed]
- Mellody, K.; Kendall, A. Influence of menopause and hormone replacement therapy on epidermal aging and skin biomechanical function. J. Eur. Acad. Dermatol. Venereol. 2022, 36, e576–e580. [Google Scholar] [CrossRef] [PubMed]
- Gasser, S.; Heidemeyer, K. Impact of progesterone on skin and hair in menopause—A comprehensive review. Climacteric 2021, 24, 229–235. [Google Scholar] [CrossRef] [PubMed]
- Manson, J.E.; Chlebowski, R.T. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women’s Health Initiative randomized trials. JAMA 2013, 310, 1353–1368. [Google Scholar] [CrossRef]
- Thornton, M.J. Estrogens and aging skin. Dermatoendocrinology 2013, 5, 264–270. [Google Scholar] [CrossRef] [PubMed]
- Desai, K.; Almeida, B. Understanding hormonal therapies: An overview for the dermatologist focused on hair. Dermatology 2021, 237, 786–791. [Google Scholar] [CrossRef]
- Cui, J.; Shen, Y. Estrogen synthesis and signaling pathways during aging: From the periphery to the brain. Trends Mol. Med. 2013, 19, 197–209. [Google Scholar] [CrossRef]
- Faubion, S.S.; Crandall, C.J.; Davis, L.; El Khoudary, S.R.; Hodis, H.N.; Lobo, R.A.; Maki, P.M.; Manson, J.E.; Pinkerton, J.V.; Santoro, N.F.; et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022, 29, 767–794. [Google Scholar]
- Mauvais-Jarvis, F.; Clegg, D.J. The Role of Estrogens in Control of Energy Balance and Glucose Homeostasis. Endocr. Rev. 2013, 34, 309–338. [Google Scholar] [CrossRef] [PubMed]
- Thornton, M.J. The biological actions of estrogens on skin. Exp. Dermatol. 2002, 11, 487–502. [Google Scholar] [CrossRef]
- Leitch, C.; Doherty, V. Women’s perceptions of the effects of menopause and hormone replacement therapy on skin. Menopause Int. 2011, 17, 11–13. [Google Scholar] [CrossRef] [PubMed]
- LePillouer-Prost, A.; Kerob, D. Skin, and menopause: Women’s point of view. J. Eur. Acad Dermatol. Venereol. 2020, 34, e267–e269. [Google Scholar] [CrossRef]
- Lephart, E.D. A review of the role of estrogen in dermal aging and facial attractiveness in women. J. Cosmet. Dermatol. 2018, 17, 282–288. [Google Scholar] [CrossRef] [PubMed]
- Blume-Peytavi, U.; Atkin, S. Skin academy: Hair, skin, hormones, and menopause—Current status/knowledge on managing hair disorders in menopausal women. Eur. J. Dermatol. 2012, 22, 310–318. [Google Scholar] [CrossRef]
- Akiba, S.; Shinkura, R. Influence of chronic UV exposure and lifestyle on facial skin photo-aging-results from a pilot study. J. Epidemiol. 1999, 9 (Suppl. 6), S136–S142. [Google Scholar] [CrossRef]
- Wolff, E.; Pal, L. Skin wrinkles and rigidity in early postmenopausal women vary by race/ethnicity: Baseline characteristics of the skin ancillary study of the KEEPS trial. Fertil. Steril. 2011, 95, 658–662.e1-3. [Google Scholar] [CrossRef]
- Wend, K.; Wend, P.; Krum, S.A. Tissue-specifc effects of loss of estrogen during menopause and aging. Front. Endocrinol. 2012, 3, 19. [Google Scholar] [CrossRef]
- Calleja-Agius, J.; Muscat-Baron, Y. Skin aging. Menopause Int. 2007, 13, 60–64. [Google Scholar] [CrossRef]
- Brincat, M.P.; Baron, Y.M. Estrogens and the skin. Climacteric 2005, 8, 110–123. [Google Scholar] [CrossRef] [PubMed]
- Brincat, M.; Kabalan, S. A study of decreasing skin collagen content, thickness, and bone mass in postmenopausal women. Obstet Gynecol. 1987, 70, 840–845. [Google Scholar]
- Reilly, D.M.; Lozano, J. Skin collagen through the life stages: Importance for skin health and beauty. Plast. Aesthet. Res. 2021, 8, 2. [Google Scholar] [CrossRef]
- Varani, J.; Dame, M.K. Decreased collagen production in chronologically aged skin: Roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am. J. Pathol. 2006, 168, 1861–1868. [Google Scholar] [CrossRef] [PubMed]
- Wilkinson, H.N.; Hardman, M.J. A role for estrogen in skin aging and dermal biomechanics. Mech. Ageing Dev. 2021, 197, 111513. [Google Scholar] [CrossRef]
- Pierard, G.E.; Humbert, P. Revisiting the cutaneous impact of oral hormone replacement therapy. Biomed. Pes. Int. 2013, 2013, 971760. [Google Scholar] [CrossRef]
- Wolff, E.F.; Narayan, D. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil. Steril. 2005, 84, 285–288. [Google Scholar] [CrossRef] [PubMed]
- Guinot, C.; Malvy, D. Effect of hormonal replacement therapy on skin biophysical properties of menopausal women. Skin Res. Technol. 2005, 11, 201–204. [Google Scholar] [CrossRef]
- Ashcroft, G.S.; Dodsworth, J. Estrogen accelerates cutaneous wound healing associated with increased TGF-beta1 levels. Nat. Med. 1997, 3, 1209–1215. [Google Scholar] [CrossRef]
- Baulieu, E.E.; Thomas, G. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue. Proc. Natl. Acad. Sci. USA 2000, 97, 4279–4284. [Google Scholar] [CrossRef]
- Diamond, P.; Cusan, L. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J. Endocrinol. 1996, 150, S43–S50. [Google Scholar] [CrossRef]
- Savoia, P.; Raina, G. Anti-oxidative effects of 17 β-estradiol and genistein in human skin fibroblasts and keratinocytes. J. Dermatol. Sci. 2018, 92, 62–77. [Google Scholar] [CrossRef]
- Bottai, G.; Mancina, R. 17 β-estradiol protects human skin fibroblasts and keratinocytes against oxidative damage. J. Eur. Acad. Dermatol. Venereol. 2013, 27, 1236–1243. [Google Scholar] [CrossRef] [PubMed]
- Stevenson, S.; Thornton, J. Effect of estrogens on skin aging and the potential role of SERMs. Clin. Interv. Aging 2007, 2, 283–297. [Google Scholar] [PubMed]
- Son, E.D.; Lee, J.Y. Topical Application of 17 β-Estradiol Increases Extracellular Matrix Protein Synthesis by Stimulating TGF-β Signaling in Aged Human Skin In Vivo. J. Investig. Dermatol. 2005, 124, 1149–1161. [Google Scholar] [CrossRef] [PubMed]
- Raine-Fenning, N.J.; Brincat, M.P.; Muscat-Baron, Y. Skin aging and menopause: Implications for treatment. Am. J. Clin. Dermatol. 2003, 4, 371–378. [Google Scholar] [CrossRef] [PubMed]
- Wines, N.; Willsteed, E. Menopause and the skin. Australas. J. Dermatol. 2001, 42, 149–160. [Google Scholar] [CrossRef]
- Horstman, A.M.; Dillon, E.L. The role of androgens and estrogens on healthy aging and longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67, 1140–1152. [Google Scholar] [CrossRef]
- Borda, L.J.; Wong, L.L. Bioidentical hormone therapy in menopause: Relevance in dermatology. Dermatol. Online J. 2019, 25, 13030/qt4c20m28z. [Google Scholar] [CrossRef]
- Siyam, T.; Yuksel, N. Beliefs about bioidentical hormone therapy: A cross-sectional survey of pharmacists. Maturitas 2013, 74, 196–202. [Google Scholar] [CrossRef]
- Conaway, E. Bioidentical hormones: An evidence-based review for primary care providers. J. Am. Osteopath Assoc. 2011, 111, 153–164. [Google Scholar]
- Gelfand, M.M.; Wiita, B. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature, 1941 to 1996. Clin. Ther. 1997, 19, 383–404; discussion 367–368. [Google Scholar] [CrossRef]
- Davis, S.R.; Moreau, M. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 2008, 359, 2005–2017. [Google Scholar] [CrossRef]
- Lobo, R.A.; Rosen, R.C. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil. Steril. 2003, 79, 1341–1352. [Google Scholar] [CrossRef]
- Shufelt, C.L.; Braunstein, G.D. Safety of testosterone use in women. Maturitas 2009, 63, 63–66. [Google Scholar] [CrossRef]
- Lattouf, C.; Miteva, M. Connubial androgenetic alopecia. Arch. Dermatol. 2011, 147, 1329–1330. [Google Scholar] [CrossRef]
- Shelton, M.A.; Chon, S. Multiple melanomas developing after bioidentical hormone replacement therapy. J. Am. Acad. Dermatol. 2015, 72, AB173. [Google Scholar]
- Marzagalli, M.; Casati, L. Estrogen Receptor beta Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE 2015, 10, e0134396. [Google Scholar] [CrossRef]
- Tang, J.Y.; Spaunhurst, K.M. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: Women’s health initiative randomized trials. J. Natl. Cancer Inst. 2011, 103, 1469–1475. [Google Scholar] [CrossRef]
- Files, J.A.; Kransdorf, L.N. Bioidentical hormone therapy: An assessment of provider knowledge. Maturitas 2016, 94, 46–51. [Google Scholar] [CrossRef]
- Kim, S.W.; Yoon, H.S. Tamoxifen-induced melasma in a postmenopausal woman. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 1199–1200. [Google Scholar] [CrossRef]
- Ortonne, J.P.; Arellano, I. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J. Eur. Acad. Dermatol. Venereol. 2009, 23, 1254–1262. [Google Scholar] [CrossRef]
Variables | Total (n = 464) |
---|---|
Age (years) | 59.1 ± 8.4 |
Elderly (≥60 years)—% (n) | 46.8 (217) |
Age at menopause—% (n) | 48.9 ± 4.7 |
Skin type—% (n) | |
Oily | 11.0 (51) |
Mixed | 49.4 (229) |
Dry | 26.7 (124) |
Sensitive | 10.3 (48) |
Others | 2.6 (12) |
Surgical menopause—% (n) | 15.4 (70) |
Menopause affected my quality of life—% (n) | |
Totally agree | 31.4 (144) |
Partially agree | 37.3 (171) |
Do not agree nor disagree | 10.3 (47) |
Partially disagree | 10.5 (48) |
Totally disagree | 10.5 (48) |
Clinical symptoms after menopause—% (n) | |
Vaginal atrophy | 26.3 (122) |
Fat increase | 39.9 (176) |
Tiredness or lack of energy | 43.5 (202) |
Hair growth on the face | 22.4 (104) |
Decreased libido | 55.0 (255) |
Hot flashes | 56.3 (261) |
Insomnia | 51.7 (240) |
Emotional lability | 40.7 (189) |
Osteoporosis | 19.2 (89) |
Weight gain | 45.0 (209) |
Skin dryness | 1.3 (6) |
Others | 9.3 (43) |
Sought medical treatment due to menopausal symptoms— | 73.5 (341) |
% (n) | |
Change in skin | 10.1 (47) |
Hot flashes | 42.7 (198) |
Insomnia | 26.9 (125) |
Urogenital atrophy | 9.1 (42) |
Emotional lability | 26.7 (66) |
Other | 14.2 (43) |
Menopause affected your self-esteem—% (n) | |
Totally agree | 24.8 (114) |
Partially agree | 27.8 (128) |
Do not agree nor disagree | 14.1 (65) |
Partially disagree | 9.1 (42) |
Totally disagree | 24.1 (111) |
Did you receive information about the effects of menopause on skin, hair and nails from your gynecologist and/or dermatologist?—% (n) | 52.9 (243) |
Do you feel comfortable talking to your dermatologist about menopause—% (n) | |
Totally agree | 70.6 (320) |
Partially agree | 9.9 (45) |
Do not agree nor disagree | 13.9 (63) |
Partially disagree | 2.0 (9) |
Totally disagree | 3.5 (16) |
Menopause has affected the quality of your skin.—% (n) | |
Totally agree | 46.5 (212) |
Partially agree | 31.1 (142) |
Do not agree nor disagree | 11.4 (52) |
Partially disagree | 5.9 (27) |
Totally disagree | 5.0 (23) |
Skin changes—% (n) | |
Skin thinning | 29.5 (137) |
Gloss loss | 41.8 (194) |
Increase in bruises, bruises (purple spots) | 14.0 (65) |
Sagging | 66.8 (310) |
Stains | 34.1 (158) |
More inflamed/irritated skin | 8.6 (40) |
More oily skin/acne | 6.0 (28) |
More sensitive skin | 14.4 (67) |
Dryness | 51.3 (238) |
Increased wrinkles | 45.5 (211) |
Worsening of dark circles | 30.2 (140) |
Other | 3.7 (17) |
Menopause affected the quality of your hair—% (n) | |
Totally agree | 43.8 (201) |
Partially agree | 28.3 (130) |
Do not agree nor disagree | 11.1 (51) |
Partially disagree | 5.9 (27) |
Totally disagree | 10.9 (50) |
What changes have you noticed in your hair?—% (n) | |
Thread thinning | 36.4 (169) |
Volume decrease | 44.6 (2073) |
Thicker yarn | 4.7 (22) |
More brittle | 22.8 (106) |
Many white threads | 36.4 (169) |
Gloss loss | 25.4 (118) |
Hair loss | 46.3 (215) |
Dryness | 28.9 (134) |
Others | 1.7 (8) |
Menopause affected the quality of your nails—% (n) | |
Totally agree | 39.0 (176) |
Partially agree | 28.2 (127) |
Do not agree nor disagree | 11.5 (52) |
Partially disagree | 6.4 (29) |
Totally disagree | 14.9 (67) |
What changes have you noticed in your nails?—% (n) | |
Peeling | 35.8 (166) |
Decrease in growth | 18.5 (86) |
Streaks on the nail | 26.9 (125) |
Fragile and/or brittle | 55.8 (259) |
Other | 1.3 (6) |
Treats or has already treated menopause symptoms with HRT—% (n) | 46.6 (216) |
HRT method uses/used—% (n) | |
Pill | 43.6 (98) |
Transdermal gel | 43.1 (97) |
Hormone implant | 10.7 (24) |
Other | 2.7 (6) |
Did you take androgen therapy (DHEA, testosterone or gestrinone) after menopause?—% (n) | |
Yes | 21.5 (96) |
No | 78.0 (348) |
I don’t remember | 0.4 (2) |
You have been well advised by your gynecologist/endocrinologist about the risks and benefits of HRT—% (n) | |
Totally agree | 48.6 (211) |
Partially agree | 15.4 (67) |
Do not agree nor disagree | 18.0 (78) |
Partially disagree | 7.6 (33) |
Totally disagree | 10.4 (45) |
Are you or were afraid to start HRT—% (n) | |
Totally agree | 36.5 (155) |
Partially agree | 19.5 (83) |
Do not agree nor disagree | 18.4 (78) |
Partially disagree | 6.6 (28) |
Totally disagree | 19.1 (81) |
You were informed that HRT would bring benefits to your skin, hair and nails—% (n) | |
Totally agree | 42.6 (180) |
Partially agree | 17.3 (73) |
Do not agree nor disagree | 20.1 (85) |
Partially disagree | 5.2 (22) |
Totally disagree | 14.9 (63) |
Improvement of symptoms after HRT—% (n) | 36.8 (169) |
Have you had any adverse effects on your skin while taking HRT?—% (n) | |
Acne | 3.9 (18) |
Seborrhea | 1.5 (7) |
Increased body hair | 9.3 (43) |
Spots on the face | 5.4 (25) |
Weight gain or increased appetite | 14.9 (69) |
Other | 2.6 (12) |
There is a lack of cosmetic products aimed for menopausal women—% (n) | 74.0 (309) |
What specific menopause products would you use?—% (n) | |
Facial moisturizing creams | 66.8 (310) |
Moisturizing body creams | 59.5 (276) |
Intimate moisturizing creams | 40.3 (187) |
Facial whitening creams | 35.8 (166) |
Neck creams | 53.9 (250) |
Eye area creams | 50.0 (232) |
Nail strengtheners | 48.1 (223) |
Shampoos and hair masks | 43.1 (200) |
Facial sunscreens | 47.6 (221) |
Facial soaps | 34.7 (161) |
Other | 2.4 (11) |
Variables | X2 | p |
---|---|---|
HRT × Skin Quality (n = 102) | 0.292 | 0.589 |
HRT × Hair Quality (n = 104) | 3.307 | 0.069 |
HRT × Nail quality (n = 81) | 0.076 | 0.786 |
Androgen therapy × Skin Quality (n = 51) | 5.810 | 0.055 |
Androgen therapy × Hair quality (n = 53) | 6.519 | 0.038 |
Androgen therapy × Nail quality (n = 36) | 3.183 | 0.204 |
HRT × Improvement of symptoms (n = 159) | 78.956 | <0.001 |
Sought care due to symptoms × HRT (n = 197) | 58.794 | <0.001 |
Sought care due to symptoms × Improvement in symptoms (n = 158) | 16.984 | <0.001 |
Hormone Type | Dermatologic Benefit (%) | Dermatologic Side Effect (%) | References |
---|---|---|---|
Estradiol | Decreases skin atrophy and xerosis (31%). | Skin irritation (20%) (topical treatments only); Localized allergic reaction (<1%) | [26,27,30,31,32,39] |
Testosterone | Decreases skin atrophy | Acne (5.6–50%); Increased facial hair growth (11.6–19.6%); Hirsutism (6–36%) | [39,42,43,44,45] |
DHEA | Decreases skin atrophy (73%) | Acne (23%); Increased sebum production (64%); Skin oiliness and elasticity changes (41–89%) | [30,31,39] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bravo, B.; Penedo, L.; Carvalho, R.; Dal Vesco, C.; Calomeni, M.; Gapanowicz, D.; Kemen, E.; Paes, R.; Renke, G. Dermatological Changes during Menopause and HRT: What to Expect? Cosmetics 2024, 11, 9. https://doi.org/10.3390/cosmetics11010009
Bravo B, Penedo L, Carvalho R, Dal Vesco C, Calomeni M, Gapanowicz D, Kemen E, Paes R, Renke G. Dermatological Changes during Menopause and HRT: What to Expect? Cosmetics. 2024; 11(1):9. https://doi.org/10.3390/cosmetics11010009
Chicago/Turabian StyleBravo, Bruna, Lais Penedo, Raquel Carvalho, Carolina Dal Vesco, Mariana Calomeni, Debora Gapanowicz, Elaine Kemen, Raphaela Paes, and Guilherme Renke. 2024. "Dermatological Changes during Menopause and HRT: What to Expect?" Cosmetics 11, no. 1: 9. https://doi.org/10.3390/cosmetics11010009
APA StyleBravo, B., Penedo, L., Carvalho, R., Dal Vesco, C., Calomeni, M., Gapanowicz, D., Kemen, E., Paes, R., & Renke, G. (2024). Dermatological Changes during Menopause and HRT: What to Expect? Cosmetics, 11(1), 9. https://doi.org/10.3390/cosmetics11010009